FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

708 letters match. Newest first.

  1. Microvascular Tissue, Inc.

    FDA says Microvascular Tissue's mVASC wound product is an unapproved drug and unlicensed biologic, made without validated processes.

    High risk
  2. Longford Water Company LLC

    FDA warns Longford Water Company that its bottled drinking water was made under insanitary conditions and without required treatment validation and testing.

    High risk
  3. North Creek Farm

    FDA warns North Creek Farm that its shell eggs are unsafe under food law because it lacked Salmonella Enteritidis controls.

    High risk
  4. Seaway Pharma Inc.

    FDA cited Seaway Pharma for manufacturing-quality rule violations in OTC oral liquid drugs, including release and component-testing failures.

    High risk
  5. CDL Services, Inc. DBA Technichem

    FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.

    High risk
  6. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk
  7. Envoy Medical Inc.

    Envoy Medical in Saint Paul, MN was cited for quality system failures in making its Esteem II Implantable Hearing System, including slow complaint investigations and missed cleanroom contamination risks.

    High risk
  8. Rhyz Analytical Labs

    FDA warned Rhyz Analytical Labs, a contract drug testing lab, that inadequate microbial failure investigations and quality oversight made tested drugs adulterated.

    High risk
  9. Turbare Manufacturing

    FDA warns outsourcing facility Turbare Manufacturing of Conway, Arkansas, for making sterile drugs under insanitary conditions.

    High risk
  10. Handelnine Global, LLC dba Navafresh

    Navafresh sells unapproved Ayurvedic drugs online, and its Rheumacare Capsules contain about 7,000 times the lead level of concern.

    High risk
  11. Owen Biosciences, Inc.

    Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.

    High risk
  12. Cdymax India Pharma Private Limited

    FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.

    High risk
  13. Seema International

    FDA warns Seema International over unclean API equipment, missing stability data, and quality-unit failures after inspection; APIs adulterated.

    High risk
  14. Siddha Flower Essences, LLC., dba Siddha Remedies

    FDA cites Siddha Remedies, a maker of children's homeopathic drugs, for untested water and botanicals and microbial contamination.

    High risk
  15. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  16. DermaRite Industries, LLC

    DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.

    High risk
  17. Uriel Pharmacy, Inc.

    Uriel Pharmacy's homeopathic ampule drugs are unapproved new drugs and were made under serious CGMP violations.

    High risk
  18. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  19. Miers Laboratories, Ltd

    FDA warns Miers Laboratories over manufacturing violations and places import alert on its drugs.

    High risk
  20. Taizhou Kangping Medical Science and Technology Co., Ltd.

    FDA warns Taizhou Kangping about over-the-counter drugs labeled sterile that were not sterilized.

    High risk
  21. Apotex Inc.

    FDA cited Apotex's Richmond Hill sterile plant for failed investigations and aseptic contamination risks, prompting recalls.

    High risk
  22. Liebel-Flarsheim Company LLC

    Liebel-Flarsheim's Raleigh, NC sterile drug plant failed to investigate microbial and endotoxin test failures and let cleanrooms and equipment fall into disrepair.

    High risk
  23. Scientific Protein Laboratories, LLC

    FDA warns Scientific Protein Laboratories over manufacturing failures in animal-derived APIs, including equipment particles and inadequate investigations.

    High risk
  24. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  25. The Tranzonic Companies/Innocore Sales & Marketing Inc.

    FDA says Innocore Sales & Marketing, an over-the-counter drug manufacturer, lacked finished-product, component, stability and quality-unit controls.

    High risk
  26. Contec Medical Systems Co., Ltd.

    FDA warns Chinese device maker Contec Medical Systems over quality system failures; its patient monitors and ultrasound devices face US border detention.

    High risk
  27. Acme United Corporation

    Acme United Corporation made antiseptic wipes with contaminated water and released sterile drugs without sterility testing.

    High risk
  28. Foshan Yiying Hygiene Products Co., Ltd.

    Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.

    High risk
  29. Guangxi Yulin Pharmaceutical Group Co. Ltd.

    FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.

    High risk
  30. BRS Analytical Services, LLC

    BRS Analytical Services, LLC made sterile OTC drugs in an unsuitable aseptic facility and recalled them over sterility assurance.

    High risk
  31. Health and Natural Beauty USA Corp.

    FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.

    High risk
  32. Naturich Cosmetique Labs

    FDA warned Naturich Cosmetique Labs over inadequate manufacturing controls for over-the-counter topical drugs, including contaminated water and untested ingredients.

    High risk
  33. Creative Essences, Inc.

    FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.

    High risk
  34. Dixon Investments Inc. dba ARI

    FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.

    High risk
  35. Ogle Cattle Company, Inc.

    Ogle Cattle Company, a Texas feedlot, sold cattle for slaughter with ceftiofur residues above the allowed level and kept no treatment records.

    High risk
  36. Valentine Enterprises, Inc.

    FDA warned Valentine Enterprises that its dietary supplements were adulterated by manufacturing violations and misbranded by label errors.

    Medium
  37. Chengdu Brilliant Biopharmaceutical Co., Ltd.

    FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.

    High risk
  38. The Richline Group, Inc.

    FDA warns Richline Group over unapproved Inverness ear care products and quality-system failures.

    High risk
  39. Columbia Cosmetics Manufacturing Inc.

    Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.

    High risk
  40. Yangzhou Yulou Paper Products Co., Ltd.

    FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.

    High risk
  41. Mericon Industries, Inc.

    Mericon Industries sold Florical and Meribin supplements with unapproved drug claims for osteoporosis and serious manufacturing and labeling failures.

    High risk
  42. Shirish M. Gadgeel, M.D.

    Detroit clinical investigator Dr. Shirish Gadgeel enrolled ineligible subjects and missed required consent for genetic testing in drug trials.

    High risk
  43. Amneal Pharmaceuticals, LLC

    FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.

    High risk
  44. Wisconsin Pharmacal Company, LLC

    FDA warns Wisconsin Pharmacal over OTC drug manufacturing violations, including released rejected product and S. aureus contamination.

    High risk
  45. Chromatography Institute of America dba Compounder’s International Analytical Laboratory

    FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.

    High risk
  46. Synergy Animal Products, Inc.

    Synergy Animal Products marketed unapproved animal drugs for dairy cows with inadequate directions and major manufacturing violations.

    High risk
  47. Miach Orthopaedics

    FDA warns Miach Orthopaedics over quality-system failures in manufacturing its BEAR ACL Implant, including sterility monitoring and nonconforming product controls.

    High risk
  48. Jiangsu Kerbio Medical Technology Group Co.

    FDA cites Jiangsu Kerbio Medical Technology Group for serious GLP violations in medical device safety testing.

    High risk
  49. Meds For Vets, LLC

    Meds For Vets compounded unapproved animal drugs from bulk substances and failed manufacturing quality rules, including sterility controls.

    High risk
  50. Anhui Hanbon Daily Chemical Co., Ltd.

    FDA warns Anhui Hanbon Daily Chemical over CGMP failures in OTC drugs, including use of an incorrect excipient and untested ingredients.

    High risk